Decheng Capital LLC Reduces Position in 4D Molecular Therapeutics, Inc. $FDMT

Decheng Capital LLC decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 61.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 92,748 shares of the company’s stock after selling 146,762 shares during the period. 4D Molecular Therapeutics comprises approximately 0.1% of Decheng Capital LLC’s portfolio, making the stock its 18th biggest holding. Decheng Capital LLC’s holdings in 4D Molecular Therapeutics were worth $806,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd bought a new stake in 4D Molecular Therapeutics during the 1st quarter valued at $39,000. Los Angeles Capital Management LLC purchased a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at $42,000. Quadrature Capital Ltd bought a new stake in 4D Molecular Therapeutics in the 2nd quarter worth $42,000. Farther Finance Advisors LLC grew its holdings in 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after acquiring an additional 2,674 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics in the first quarter valued at about $46,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Trading Down 1.4%

Shares of NASDAQ:FDMT opened at $8.33 on Monday. The stock has a fifty day simple moving average of $8.63 and a two-hundred day simple moving average of $9.06. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.23 and a 12-month high of $12.34. The stock has a market capitalization of $475.89 million, a price-to-earnings ratio of -2.22 and a beta of 2.99.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on FDMT. Barclays started coverage on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 21st. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Chardan Capital reiterated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, December 18th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 7th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.67.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.